Potential negative impact of reputed regulators' decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis.
<h4>Background</h4>Many new cancer drugs are being approved by reputed regulatory authorities without evidence of overall survival benefit, quality of life improvement, and often based on clinical trials at high risk of bias. In recent years, most Latin American (LA) countries have refor...
Guardado en:
Autores principales: | Carlos E Durán, Martín Cañás, Martín Urtasun, Monique Elseviers, Robert Vander Stichele, Thierry Christiaens |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bfcfd22f30d9492198028516559f1253 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dialectic of Honor and Reputation. On Limits of Reputation Management Efficiency
por: V. B. Aleksandrov
Publicado: (2021) -
Universities' reputation /
Publicado: (2015) -
Uncovering the stability status of the reputed reference genes in breast and hepatic cancer cell lines.
por: Gilar Gorji-Bahri, et al.
Publicado: (2021) -
Uncovering the stability status of the reputed reference genes in breast and hepatic cancer cell lines
por: Gilar Gorji-Bahri, et al.
Publicado: (2021) -
Judgments in the Sharing Economy: The Effect of User-Generated Trust and Reputation Information on Decision-Making Accuracy and Bias
por: Mircea Zloteanu, et al.
Publicado: (2021)